Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(5):301; doi:10.1093/jnci/djj113
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McNeil, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McNeil, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

Nicotine Vaccines Move Toward Pivotal Trials

Caroline McNeil

The first 10% of the full text of this article appears below.

Three candidate vaccines to help smokers quit reached development landmarks in 2005, and at least two of them are headed toward phase III trials, according to the three companies involved. In randomized trials, all three vaccines elicited antibodies to nicotine and increased quit rates compared with . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?